Ideas Weave Every Narrative with AI.
Moderna’s first positive Phase 3 for mRNA neoantigen therapy in melanoma is a historic breakthrough. But the real story isn’t the stock surge—it’s the platform’s potential to turn cancer into a chronic condition. The 90% clinical trial failure rate casts a long shadow, and the hardest part—scalability and cost—is just beginning.
Prediction markets on platforms like Kalshi and Polymarket now allow betting on clinical trial outcomes. While critics scream about insider trading, the real threat is far more insidious: these markets financially incentivize the subtle manipulation of trial design and human suffering. We cannot turn hospitals into casinos.
Prediction markets on drug trials promise to reveal the truth before official results. But there’s a catch: they only work if insiders can trade on non-public data—which is illegal. The SEC and FDA are heading for a collision that will decide whether these markets become life-saving tools or just sophisticated casinos.
Israeli scientists discovered that Viagra’s active ingredient can stop cancer from spreading, backed by 20 years of data from 5 million patients. But because it’s a cheap generic drug, no pharmaceutical company will fund the clinical trials needed to prove it. This is a story of hope — and a broken system that prefers expensive treatments over effective ones.